

A case series of eight amateur athletes: exercise-induced pre-/syncope during the Zurich Marathon 2023

Greta Hametner (1)¹, Doris Eis (1)², Muriel Kruijver¹, Michael Stiefel¹, Jan Gerrit van der Stouwe (1)^{1,3}, Melina Stüssi-Helbling (1)⁴, Anja Forrer (1)⁴, and David Niederseer (1)^{1,5,6}*

¹Department of Cardiology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091 Zurich, Switzerland; ²Department of Emergency Medicine, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091 Zurich, Switzerland; ³Department of Cardiology, University Hospital Basel, University of Basel, Petersgraben 4, 4031 Basel, Switzerland; ⁴Department of Internal Medicine, Clinic for Internal Medicine, City Hospital Zurich, Triemli, Birmensdorferstrasse 497, 8063 Zürich, Switzerland; ⁵Hochgebirgsklinik, Medicine Campus Davos, Herman-Burchard-Strasse 1, 7265 Davos Wolfgang, Switzerland; and ⁶Christine Kühne Center for Allergy Research and Education (CK-CARE), Medicine Campus Davos, Herman-Burchard-Strasse 1, 7265 Davos Wolfgang, Switzerland

Received 25 November 2023; revised 26 March 2024; accepted 16 April 2024; online publish-ahead-of-print 19 April 2024

Background	Marathon running poses unique cardiovascular challenges, sometimes leading to syncopal episodes. We present a case series of athletes who experienced pre-/syncope during the Zurich Marathon 2023, accompanied by elevated cardiac biomarkers.
Case summary	Eight athletes (2 females, 6 males) aged 21–35 years, with pre-/syncope and various additional diverse symptoms such as dizziness and palpitations during the (half-)marathon, were admitted to two emergency departments in Zurich, Switzerland. Clinical evaluations included electrocardiogram, echocardiography, telemetry, coronary computed tomography (CT) scans, and cardiac biomarker assessments. High-sensitive troponin T (hs-cTnT) was elevated in all cases at initial assessment and returned to normal at follow-up. All athletes who received CT scans had normal coronary and brain CT results. None of the eight athletes had under- lying cardiovascular disease. Renal function normalized post-admission, and neurological symptoms resolved within hours. Creatinine levels indicated transient acute kidney injury. A common feature was inexperience in running, inadequate race prepar- ation, particularly regarding fluid, electrolyte, and carbohydrate intake, along with pacing issues and lack of coping strategies with heat.
Discussion	From a clinician perspective, the case series highlights the challenge in the management of patients with a pre-/syncopal event during strenuous exercise and elevated cardiac biomarkers. Diverse initial symptoms prompted tailored investigations. Adequate training, medical assessments, and awareness of syncope triggers are essential for marathon participants. Caution and pacing strategies are crucial, especially among novices in competitive running. This information is pertinent given the growing popularity of marathon events and prompts a standardized diagnostic approach after these events.
Keywords	Marathon • Collapse • Syncope • Cardiac biomarkers • Case series
ESC curriculum	5.2 Transient loss of consciousness • 8.1 Sports cardiology

* Corresponding author. Tel: +41 79 919 96 93, Email: david.niederseer@gmx.at

Handling Editor: Elena Cavaretta

Peer-reviewers: Annachiara Pingitore; Clea Simone Sabino de Souza Colombo; David Oxborough

Compliance Editor: Anas Mohamad Hashem

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

[©] The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.


Learning points

- The case series highlights syncope and elevated cardiac biomarkers in athletes after intense exercise, likely due to 'exercise-induced elevation' without known cardiac issues.
- Athletes with pre-/syncope commonly share factors like inexperience, inadequate training, and poor race preparation.
- Pre-participation screening is crucial for athletes' health, safety, and performance in sports management.
- The series stresses the need for immediate medical attention during (half-)marathons to investigate serious causes of pre-/syncope like spontaneous coronary artery dissection, acute coronary syndrome peri-/myocarditis, or channelopathies.

Introduction

Marathon running is a strenuous endurance activity that places substantial demands on the cardiovascular system. Athletes participating in marathons may occasionally experience cardiovascular events, including syncope or presyncope. These events can be alarming for both athletes and medical personnel, prompting further investigation to understand their underlying mechanisms and implications. Syncope in the emergency department requires a standardized approach to ideally categorize it as orthostatic hypotension, reflex syncope, or cardiac syncope. Cardiac biomarker elevation during or after a marathon may indicate damage to the heart muscle.¹ There are many factors that can contribute to such damage, including physical overexertion, dehydration, heat stroke, underlying cardiac conditions, and other medical conditions. Whether exercise-induced elevation of cardiac biomarkers is clinically relevant is still under debate.

Summary figure



Patient 1

A 26-year-old female marathon runner experienced back pain after 39 km and syncope at km 41. Initial vital signs included a blood pressure (BP) of 99/57 mmHg, heart rate of 85 b.p.m., and normal oxygen saturation. Her initial electrocardiogram (ECG) was unremarkable, and troponin levels were not measured. Creatinine was elevated with 109 µmol/L. A transthoracic echocardiogram (TTE) showed a left ventricular ejection fraction (LVEF) of 59% without valvular disease, and 48 h ECG monitoring showed continuous sinus rhythm without relevant arrhythmia. Cardiorespiratory fitness assessment revealed a VO_{2max} of 53.92 mL/kg/min, a maximum exercise capacity of 210 W on cycle ergometry (175% of age-predicted maximum), and a VE/ VCO₂ Slope of 22.54. She took daily lisdexamfetamine (30 mg/day) for attention deficit hyperactivity disorder (ADHD), is a law student, an experienced runner with five marathons, and has trained for 14 years, including eight 20 km runs in preparation. During follow-up, there were no abnormalities noted in the laboratory analysis, ECG, 48 h ECG monitoring, cardiopulmonary exercise testing (CPET), or echocardiography. The use of supplements and doping was denied and there was no family history of sudden cardiac death (SCD).

Patient 2

A 35-year-old male half-marathon runner experienced dizziness and disorientation after 20.5 km, nearly fainting. Initial vital signs showed a BP of 115/56 mmHg, heart rate of 67 b.p.m., SpO₂ at 98%, and body temperature of 37.5°C. The initial ECG was normal. Lab results showed elevated high-sensitivity troponin T (163 ng/mL), creatine kinase (1538 U/L), and creatinine (139 µmol/L) levels (*Figure 1*). Follow-up assessments with TTE revealed an LVEF of 53%, no valvular disease, and sinus rhythm on a 48 h Holter ECG. Cardiorespiratory fitness showed a VO_{2max} of 43.26 mL/min/kg, a maximum exercise capacity of 284 W (135% of age-predicted), and a VE/VCO₂ Slope of 27.53. The patient had slightly

elevated BP and participated in 10 km races yearly. He works as an engineer. He typically trains two to three times a week, including interval training and 8–10 km runs. This has been his second half-marathon, with a personal best of 1 h and 40 min. During follow-up, there were no abnormalities noted in the laboratory analysis, ECG, 48 h ECG monitoring, CPET, or echocardiography. The use of supplements and doping was denied and there was no family history of SCD.

Patient 3

A 26-year-old female half-marathon runner experienced tachycardia and dizziness at 17.5 km, followed by syncope. Initial vital signs showed a BP of 102/55 mmHg, heart rate of 57 bpm, SpO₂ at 99%, and a body temperature of 36.2°C. Her initial ECG was normal, and thorax and brain CT scans revealed no abnormalities. Laboratory findings showed an elevated peak troponin T (80 ng/mL), creatine kinase level (174 U/L), and creatinine level (125 µmol/L) (Figure 2). Follow-up assessments included a TTE reporting an LVEF of 59% with no valvular disease and both the ECG and a 48 h ECG monitoring showed sinus rhythm without rhythm disorders. Cardiopulmonary exercise testing revealed a VO_{2max} of 39.3 mL/min/kg, a maximum threshold of 239 W (191% of expected), and a VE/VCO₂ Slope of 24.9. The patient had experienced a viral infection 5 days before the race and was not on any medication. She is a medical student who engages in strength training twice a week and jogging three times a week, covering a total of 30 km weekly. She has completed 10 half-marathons since 2016, with a personal best time of 1 h and 52 min. The use of supplements and doping was denied and there was no family history of SCD.

Patient 4

A 27-year-old male first-time half-marathon runner experienced vomiting followed by syncope at km 18. Initial vital signs included a BP of 113/ 53 mmHg, heart rate of 75 b.p.m., SpO_2 at 94%, and a body temperature




Figure 1 Patient 2: (A) creatine kinase levels on admission and at follow-up, (B) troponin levels on admission and at follow-up, and (C) computed tomography scan of the brain after the marathon: blue arrow shows non-specific small calcification in the 4th ventricle, no bleeding, no acute territorial infarction, and normal external and internal cerebrospinal fluid spaces.




Figure 2 Patient 3: (A and B) coronary computed tomography: normal coronary anatomy, no coronary atherosclerosis. (C) Echocardiography including strain imaging reveiled normal left ventricular function.

of 36.5°C. The initial ECG was normal. Laboratory findings included a creatine kinase of 151 IU/L and creatinine levels of 133 µmol/L, but troponin T was not measured. Follow-up assessments with TTE revealed an LVEF of 52% without valvular disease. Both the ECG and 48 h ECG monitoring showed sinus rhythm without rhythm disorders. Cardiopulmonary exercise testing showed a VO_{2max} of 35.2 mL/min/kg, a maximum threshold of 216 W (94% of expected), and a VE/VCO₂ Slope of 20.30. The patient had no significant past medical history and was not on medication. Professionally, he works as a depositary. He initiated targeted running training with coaching in December 2022, losing ~16 kg. His regimen consisted of six sessions per week with a goal of a 2 h, 10 min half-marathon, completing several 20 km runs in preparation. The use of supplements and doping was denied and there was no family history of SCD.

Patient 5

A 32-year-old male, a former professional football player, experienced syncope at km 41 during his run, followed by shivering and amnesia upon regaining consciousness. Initial vital signs included a BP of 107/ 55 mmHg, heart rate of 67 b.p.m., SpO₂ at 96%, and a body temperature of 37.1°C. The initial ECG revealed non-significant ST-segment elevation in the inferior leads. Laboratory findings showed elevated peak troponin T (117 ng/L), creatine kinase (1047 IU/L), and creatinine (178 µmol/L) levels. Follow-up assessments included a TTE with an LVEF of 53% without valvular disease. Both the ECG and a 48 h ECG monitoring showed sinus rhythm with no rhythm disorders. The patient was not on regular medication. Cardiopulmonary exercise testing showed a VO $_{2max}$ of 43.38 mL/min/kg, a maximum threshold of 243 W (115% of expected), and a VE/VCO₂ Slope of 18.3. He works as a consultant in finance and had been a professional football goalkeeper until age 20 and engaged in regular running training for the past 10 years, covering around 60 km/week, often with multiple runs weekly. In preparation for the marathon, he completed five long jogs, each exceeding 40 km. The use of supplements and doping was denied and there was no family history of SCD.

Patient 6

A 36-year-old male participating in his first marathon experienced exhaustion around km 21, followed by syncope at km 32, preceded by dizziness and imbalance. Initial vital signs showed a BP of 118/59 mmHg, a heart rate of 77 b.p.m., SpO_2 at 99%, and a body temperature of 37.7°C. Laboratory results revealed elevated troponin T (146 ng/L),

a high creatine kinase (3463 U/L), and elevated peak creatinine (147 µmol/L) (*Figure 3*). Subsequent evaluations with TTE showed an LVEF of 59% with no valvular heart disease. Both the ECG and 48 h ECG monitoring showed sinus rhythm with no rhythm disorders. Cardiopulmonary exercise testing showed a VO_{2max} of 37.3 mL/kg/min, a maximum threshold of 223 W (133% of expected), and a VE/VCO₂ Slope of 24.99. The patient had a history of catching a cold 2 weeks before the race but was not on medications. He worked as a consultant in finance and resumed regular training 6 years ago, running over 10 km every other day. In preparation for the marathon, he completed five long jogs, each covering 30 km. The use of supplements and doping was denied and there was no family history of SCD.

Patient 7

A 22-year-old experienced male runner, suffered syncope, tachycardia, limited vision, and imbalance during a half-marathon at km 22. Initial assessments revealed a BP of 125/59 mmHg, heart rate of 113 b.p.m., SpO₂ of 96%, and body temperature of 38.7°C. Electrocardiogram showed sinus tachycardia and non-significant ST-segment depression in V3–V6. Troponin T (71 ng/L) and creatine kinase (6915 U/L) were substantially elevated while creatinine was normal (Figure 4). Initial TTE showed a mildly dilated left atrium immediately after the marathon and syncope, which normalized in the follow-up. In TTE, LVEF was 52% without valvular disease. Initial CT scan of the brain and heart were normal. Electrocardiogram and 48 h ECG monitoring showed normal sinus rhythm. Cardiopulmonary exercise testing showed a VO_{2max} of 44.0 mL/min/kg, max threshold of 266 W (114% of expected), and a VE/VCO₂ Slope of 22.26. There was no significant medical history or medication. He studied business management. Regarding training, he had not specifically prepared for the half-marathon. He played professional football as a winger for 7 years until 2020. Subsequently, he trained 3-4 times weekly, focusing on both strength and endurance. He also participated in university sports and jogged thrice weekly for distances up to 10 km. The use of supplements and doping was denied and there was no family history of SCD.

Patient 8

A 21-year-old male with a decade of athletic experience noted an elevated heart rate (200/min) from the start, followed by imbalance, dizziness at km 18, and syncope at km 21. Two weeks prior, he had a viral infection with fever (up to 38.5°C). He was not on medication




Figure 3 Patient 6: (A) coronary computed tomography after the marathon showing normal coronary anatomy and no coronary atherosclerosis of the left anterior descending artery, (B) electrocardiogram after the marathon, (C) creatine kinase levels after marathon and at follow-up, and (D) troponin levels after on admission and at the follow-up.




Figure 4 Patient 7: (A) mildly dilated left atrium left atrial volume index 35 mL/m² immediately after marathon/syncope, (B) normalized atrium at the follow-up after 8 weeks left atrial volume index 20 mL/m², (C) creatine kinase levels initial and at follow-up, and (D) troponin levels on admission and at follow-up.

and occasionally used tetrahydrocannabinol. He studied architecture and had no significant medical history. He participated in track and field since childhood with professional coaching. His routine involved interval runs, 3-4 track sessions weekly, and 1-2 runs spanning 10 to 20 km/week. The use of supplements and doping was denied and there was no family history of SCD.

Case series

We present a case series involving eight individuals (2 females/6 males) who received treatment after pre-/syncope during the Zurich Marathon and Half-Marathon that took place on 23 April 2023. The cases were managed in two emergency departments, namely, the City Hospital Zurich and the University Hospital Zurich. In total, 3561 people participated in the Zurich Marathon and 6388 participated in the Half-Marathon bringing the total participation to 9949 individuals. The sunny weather conditions in the morning were quite usual for Switzerland during spring with a temperature around 8°C, but during the course of the day, it became quite warm for the season, reaching up to 18°C. All cases shared common clinical features following the pre-/syncope episodes, as outlined in *Table 1*. The sports cardiological follow-up at the outpatient department of the University Clinic Zurich took place 3 months after the emergency treatment in the hospital.

Discussion

We here report a case series of eight athletes with pre-/syncope during the Zurich (Half-)Marathon 2023 that agreed to have a structured follow-up examination and also agreed to be included in this cases series.

According to guidelines for syncope of the European Society of Cardiology, our athletes displayed low-risk features, including classic prodromal symptoms preceding syncope. However, their syncope occurring during exertion categorized them as high-risk individuals.² None of the athletes reported chest discomfort upon reaching the emergency department.

Initial symptoms upon presentation varied, leading to tailored investigations. In practice, we observed diverse approaches to subsequent clinical investigations, with some athletes undergoing immediate coronary CT scans and echocardiography following elevated cardiac biomarkers.

All eight athletes underwent comprehensive screening for underlying medical conditions associated with their pre-/syncope episodes during half-/marathons. None of them had underlying cardiovascular disease. Patient 7 exhibited mild left atrial dilatation during the initial emergency department echocardiogram, which had completely resolved upon follow-up.

Endurance exercises like long-distance triathlons, marathons, and half-marathons are known to induce specific adaptations in the heart muscle. These adaptations can manifest as reduced left and/or right ventricular systolic and/or diastolic function.³ The elevated cardiac output during these events places significant strain on the heart's structures, especially in cavities with thin walls such as the right ventricle, left atrium, and right atrium. This can lead to temporary decreases in function or myocardial remodelling.^{3,4}

In a low-risk population with elevated cardiac biomarkers, performing a coronary CT scan supports risk stratification by detecting coronary artery disease, coronary anomalies, or spontaneous coronary artery dissection (SCAD) and analysing plaque composition and the tissue surrounding the vessel to pinpoint patients who are at risk of coronary events.⁵ Recent advances in CT technology have significantly improved coronary CT angiography, although its resolution remains limited for assessing small distal coronary arteries.⁶

All CT scans conducted on the athletes revealed normal results, reinforcing the concept of exercise-induced elevation in cardiac biomarkers. In the context of exercise-induced high-sensitivity troponin elevation, most studies have found no association between post-exercise troponin elevations and severity of coronary artery disease.⁵ Patients presenting post-exercise with any clinical concern for an acute coronary syndrome should undergo immediate evaluation including non-invasive and/or invasive risk stratification—irrespective of cardiac biomarker levels. However, due to its low diagnostic yield, assessment of CAD is not indicated solely on the basis of post-exercise troponin elevation.

Interestingly, we noted a concurrent elevation in creatinine levels in some athletes indicating acute kidney injury. It can be assumed that

syncope had different, and potentially mixed, underlying mechanisms, which calls for categorizing as precisely as possible. Marathon running subjects the body to various stressors, including environmental heat exposure, exercise-induced dehydration, elevated core body temperature, reduced renal blood flow, and systemic inflammation.⁷ However, during follow-up assessments, all athletes exhibited normalized renal function. Diagnosing a potential heat stroke, only the core temperature (tympanic or rectal) should be considered, as in our patients. Peripheral temperatures should not be used to define heat stroke during sports practice. Heat stroke can occur not only due to the weather but mainly due to the athlete's acclimatization conditions.

Neurological symptoms experienced by the athletes completely resolved within hours of admission to the hospital. Two athletes underwent brain CT scans that revealed no underlying pathologies. One patient had a follow-up appointment with an outpatient neurologist (Patient 7), which was also normal.

The elevated cardiac biomarkers observed in these athletes were interpreted in the context of 'exercise-induced elevation', a well-documented phenomenon in the literature. The precise mechanisms driving this phenomenon remain incompletely understood, but it is likely linked to physical stress during endurance exercise, leading to increased membrane permeability of cardiomyocytes and the passive diffusion of troponins.⁸

Three of the athletes (Patients 3, 6, and 8) had fallen ill with a viral infection. Patients 3 and 6 measured subfebrile temperatures and complained of bronchitis and rhinitis. Patient 8 also had a fever 2 weeks before the race. All patients did not feel fully recovered from the infection at the time of competition but did not want to miss the event. Therefore, further diagnostic steps were taken to exclude peri-/myocarditis and consecutive arrhythmogenic syncope. Patient 8 had a sinus tachycardia right from the start; there was no evidence of an underlying supraventricular tachycardia in the analysis of the heart rate monitor from the race, during follow-up exercise test or in the 48 h ECG monitoring. The elevated heart rate could be interpreted as sinus tachycardia.

An important differential diagnosis of syncope is also represented by channelopathies. None of our athletes showed signs of a channelopathy in both the initial and follow-up ECGs, either at rest or under exercise testing and there was no family history of sudden cardiac arrest in the medical history of each athlete. Therefore, high-lead position ECGs were not routinely performed. However, in cases of recurrent syncope, further investigations including high-lead position ECGs are warranted.

The pre-/syncope episodes had diverse causes among the athletes. A common feature was inadequate race preparation, particularly regarding fluid, electrolyte, and carbohydrate intake, along with pacing issues. Most of these athletes were inexperienced in competitive running or attempting a (half-)marathon for the first time. None of the investigated athletes had undergone a sports medical examination before participating in the competition. The correct pacing strategy in the marathon is difficult to achieve and requires thorough preparation, recreational runners should try to maintaining a consistent speed increases the likelihood of reaching the finish line compared with inconsistent pacing. The more experienced the athlete, the better they can maintain their speed.⁹ All of our examined athletes ran the first quarter of the competition at a pace significantly faster than the rest of the race, most likely in an anaerobic phase, which lead to significantly faster exhaustion and an unintentional accumulation of lactate. Competitive racing, especially among novices, demands a solid understanding of pacing strategies and proper nutritional intake for a safe and successful race.

Patient's perspective (Patient 3)

Around km 15, it got really rough. I could not run anymore and felt dizzy, like I had no control over my legs. I was staggering as if I were drunk, and the sensory overload from the crowds was overwhelming. I felt nauseous and had strange tingling sensations in my legs that went away quickly.

Perlophone5 p s		Patient 1, marathon	Patient 2, marathon	Patient 3, half-marathon	Patient 4, half-marathon	Patient 5, marathon	Patient 6, marathon	Patient 7, half-marathon	Patient 8, half-marathon
ymat 26 33 26 33 26 33 34 23 envg complaint fer pin and wyoope m m m m m m m 23 envg complaint fer pin and wyoope diorientation dizensis, syncope yyroope diorientation dizensis, yyroope, fer pin and solution fer pin and dizensis, yyroope, ments yyroope fer pin and dizensis, pin and direct rel, bin 33 133 1333 <td>re-/syncope</td> <td>S</td> <td>٩.</td> <td>S</td> <td>S</td> <td>S</td> <td>S</td> <td>S</td> <td>S</td>	re-/syncope	S	٩.	S	S	S	S	S	S
f m f m m m m m m m sytope documtation dzaresis, synope synope, sinoresis synope, sinores synope, sinor	ge, years	26	35	26	27	32	36	22	21
Bit chained Distines and syncope Tachycardia, syncope Vonting and syncope Syncope, chivenia, animatia, syncope Exhibition, animatia, syncope Tachycardia, animatia, syncope Number, animatia, syncope Syncope, chivenia, animatia, syncope Exhibition, syncope Syncope, advance, animatia, syncope Number, animatia, syncope Number, animatia, syncope Number, animatia, syncope Syncope, advance, animatia, syncope Number, animatia, syncope Number, animatia, syncope Number, animatia, syncope Number, animatia, syncope Number, animatia, syncope Number, animatia, syncope Number, animatia, syncope 85 67 77 75 85 37.1 37.7 38.7 85 37.5 36.5 37.1 37.7 38.7 38.7 86 67 77 37.7 38.7 59 59 86.5 1133 174 151 1047 34.3 50 109 139 125 133 178 146 71 109 139 133 1047 146 71 109 133 103	Xe	f	E	f	E	E	E	E	Σ
yncopedsortentationdtarines, syncopeammellaattrined vision, imbiance4120511510511301551132imbiance9571155105125113015511325957115510557677711385677775677711386989994959595365375362365371377387365375362365371377387365375362365371377387365375365371377387387365373363371377387387401717173773873874017151104734350147419191741511047343665191917415110473436651919131047343665665191917415110473463665191917415110473463665191917313310473463665191917415110473463665191917415110471467119	esenting complaint	Back pain and	Dizziness and	Tachycardia,	Vomiting and	Syncope, shivering,	Exhaustion, syncope,	Syncope, tachycardia,	Elevated heart rate,
41 205 175 18 41 22 165 9657 11556 10255 11353 10755 11894 1559 965 67 77 11353 10755 1894 1559 865 67 77 67 77 97 113 365 373 362 365 371 377 387 365 373 365 371 377 387 387 365 373 362 365 371 377 387 365 373 362 365 371 377 387 365 373 373 373 377 387 365 371 67 371 377 387 365 373 373 374 377 57-56 366 371 1077 317 374 57-56 371 381 373 373 373 <td< td=""><td></td><td>syncope</td><td>disorientation</td><td>dizziness, syncope</td><td>syncope</td><td>amnesia</td><td>dizziness, imbalance</td><td>limited vision,</td><td>imbalance, dizziness,</td></td<>		syncope	disorientation	dizziness, syncope	syncope	amnesia	dizziness, imbalance	limited vision,	imbalance, dizziness,
41 205 173 18 41 32 165 9957 11556 10255 11333 107155 11894 12559 85 67 77 71 71 113 85 67 77 71 113 365 373 36.2 36.5 37.1 37.7 38.7 365 373 36.2 36.5 37.1 37.7 38.7 365 373 36.2 36.5 37.1 37.7 38.7 86 67 71 37.7 38.7 38.7 97 167 167 167 17.4 17.4 109 139 17.4 17.3 17.4 9.9 109 139 125 133 147 9.9 109 139 125 131 107 146 71 109 139 125 131 104 147 9.9 515								imbalance	syncope
99/57 115/56 102/55 113/51 107/55 113/54 125/59 85 67 57 57 55 77 113 96 96 99 99 94 96 99 96 96 85 37.5 36.2 36.5 37.1 37.7 38.7 365 37.5 36.2 36.5 37.1 37.7 38.7 365 37.5 36.2 36.5 37.1 37.7 38.7 365 37.1 57.8 56.5 37.1 37.7 38.7 365 133 104 407 50.8 50.8 109 133 104 37.3 50.9 50.5 109 133 104 36.55 50.5 50.5 109 133 104 36.55 50.5 50.5 109 133 104 36.55 50.5 50.5 50.5 109 133 </td <td>stance at symptoms, kn</td> <td></td> <td>20.5</td> <td>17.5</td> <td>18</td> <td>41</td> <td>32</td> <td>16.5</td> <td>19</td>	stance at symptoms, kn		20.5	17.5	18	41	32	16.5	19
$\frac{8}{9}$ $\frac{6}{7}$ $\frac{7}{5}$ $\frac{7}{5}$ $\frac{6}{7}$ $\frac{7}{7}$ $\frac{113}{9}$ $\frac{8}{36}$ $\frac{9}{36}$ $\frac{9}{36}$ $\frac{7}{36}$ $\frac{7}{36}$ $\frac{113}{37}$ $\frac{113}{96}$ $\frac{1}{5}$ $\frac{1}{5}$ $\frac{1}{5}$ $\frac{1}{5}$ $\frac{1}{3}$ $\frac{1}{3}$ $\frac{1}{3}$ $\frac{1}{3}$ $\frac{1}{5}$ $\frac{1}{5}$ $\frac{1}{5}$ $\frac{1}{5}$ $\frac{1}{3}$ $\frac{1}{3}$ $\frac{1}{3}$ $\frac{1}{3}$ $\frac{1}{5}$	tial blood pressure, mmHø	99/57	115/56	102/55	113/53	107/55	118/94	125/59	117/63
98 99 94 94 96 99 96 365 375 36.2 36.5 371 377 387 365 375 36.2 36.5 371 377 387 ECG normal ECG normal ECG normal ECG normal Sinus tachycarda, non-significant non-significant 57-segment 67-segment 0 138 174 151 1047 3463 6915 109 139 125 133 178 147 99 Lub test, ECG Repression in 447 99 109 139 125 133 178 147 99 95 Sinus trythm, no sessment, terbo echocardiography 99 52 53 53	tial heart rate. b.n.m.	85	67	57	75	67	17	113	29
36537536.537.137.738.7ECG normalECG normalECG normalECG normalECG normalSinus tachycarda, non-significantSinus tachycarda, serson in V4-V616380117146711531091251337841799133104734633631561759913313378147999113317499147999914799961479996146 <td>tial oxygen saturation, SpO₂</td> <td>86</td> <td>98</td> <td>66</td> <td>94</td> <td>96</td> <td>66</td> <td>96</td> <td>6</td>	tial oxygen saturation, SpO ₂	86	98	66	94	96	66	96	6
ECG normal ECG normal ECG normal ECG normal ECG normal Sinus tachycarda, non-significant FCG normal Sinus tachycarda, non-significant - - 163 80 - 117 146 71 - - 153 174 151 1047 3463 6915 - 153 174 151 1047 3463 6915 - 153 174 151 1047 3463 6915 - 153 174 151 1047 3463 6915 - 153 133 174 151 1047 3463 6915 - 153 133 134 3463 6915 71 - 153 133 134 146 71 - - 153 148 71 71 - - 153 148 71 71 - - 153 148 71	tial body temperature (tympanic), °C	36.5	37.5	36.2	36.5	37.1	37.7	38.7	37
- 163 80 - 117 146 71 - 1538 174 151 1047 3463 6915 109 139 125 133 178 147 99 109 139 125 133 178 147 99 108 139 125 133 178 147 99 109 139 125 133 178 147 99 medical assessment medical assessment medical assessment medical assessment medical assessment medical assessment 99 CT heart and brain, cT heart and brain, cehocardiography cehocardiography heart and brain, echocardiography issessment, CT heart, assessment, Echo, CT Sinus rhythm, no Sinus rhythm, no Sinus rhythm, no Sinus rhythm, no Sinus rhythm, no Sinus rhythm, no Sinus rhythm, no Sinus rhythm, no Sinus rhythm, no Sinus rhythm, no	tial ECG	ECG normal	ECG normal	ECG normal	ECG normal	Sinus tachycardia, non-significant ST-segment depression in inferior leads	ECG normal	Sinus tachycardia, non-significant ST-segment depression in V4–V6	ECG normal
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	ial laboratory findings								
- 153 174 151 1047 3453 6915 109 139 125 133 178 147 99 Lab test, ECG, Tebest, ECG, <	sTroponinT, ng/L		163	80		117	146	71	247
109 139 125 133 178 147 99 Lab test, ECG, La	Creatine kinase, U/L		1538	174	151	1047	3463	6915	4901
Lab test, ECG,Lab test, ECG,medical assessment,assessment,assessment,assessment,Ech, CTmedical assessment,medical assessment,medical assessment,medical assessment,medical assessment,assessment, CT heart,assessment, CT heart,assessment, CT heart,assessment, CT heart,assessment, CT heart,assessment, CT heart,assessment, Echo, CTCT heart and brain,CT heart and brain,CT heart and brain,cchocardiographyechocardiographyheart and brain,cechocardiographyechocardiographyechocardiographyechocardiographyechocardiographyheart and brain,Sinus rhythm, noSinus rhythmirelevant arrhythmirelevant arrhythmirelevant arrhythmirelevant arrhythmirelevant arrhythmiSinus rhythm, noSinus rhythm, noSinus rhythm, noSinus rhythm, noSinus rhythm, noSinus rhythm, noSinus rhythmirelevant arrhythmirelevant arrhythmirelevant arrhythmirelevant arrhythmifevant arrhythmiSinus rhythm, noSinus rhythm, noSinus rhythm, noSinus rhythm, noSinus rhythm, noSinus rhythm, noSinus rhythmirelevant arrhythmirelevant arrhythmirelevant arrhythmirelevant arrhythmirelevant arrhythmiSinus rhythmSinus rhythmSinus r	Creatinine, µmol/L	109	139	125	133	178	147	66	131
medical assessment, nedical assessment, a medical assessment, CT heart and brain, ct heart and brain, ct heart and brain, ct heart and brain, chocardiographymedical assessment, medical assessment, cehocardiographymedical assessment, echocardiographymedical assessment, fehocardiographyassessment, fehocardiographyassessment, fehocardiographyassessment, fehocardiographyheart and brain, echocardiography59535359535952535359525105inus rhythm, io relevant arrhythmia5inus rhythm, io relevant arrhythmia5inus rhythm, io relevant arrhythmia5inus rhythm, io relevant arrhythmia5inus rhythm, io relevant arrhythmia5153535353535353535353545353545353545354535453545354535453545356617666767676767676717276767676767676767676727324922237492222525252525252525253567172767497276749727272727497272767497272727272749727274972727272<	Initial investigations	Lab test, ECG,	Lab test, ECG,	Lab test, ECG,	Lab test, ECG,	Lab test, ECG,	Lab test, ECG, medical	Lab test, ECG, medical	Lab test, ECG,
595359535952Sinus rhythm, noSinus rhythm, noSinus rhythm, noSinus rhythm, noSinus rhythm, noSinus rhythmiarelevant arrhythmiarelevant arrhythmiarelevant arrhythmiarelevant arrhythmiarelevant arrhythmiarelevant arrhythmiarelevant arrhythmiarelevant arrhythmiarelevant arrhythmia53.9243.2639.3035.2643.3844.01210 (175% of predicted)239 (191% of predicted)216 (94% of predicted)234 (115% of predicted)266 (114% of predicted)22.5427.5324.9020.3018.2324.9922.26		medical assessment	medical assessment, CT heart and brain, echocardiography	medical assessment, CT heart and brain, echocardiography	medical assessment		assessment, CT heart, echocardiography	assessment, Echo, CT heart and brain, echocardiography	medical assessment
Sinus rhythm, noSinus rhythm, noSinus rhythm, noSinus rhythm, noSinus rhythm, norelevant arrhythmiarelevant arrhythmiarelevant arrhythmiarelevant arrhythmiarelevant arrhythmiarelevant arrhythmiarelevant arrhythmiarelevant arrhythmiarelevant arrhythmiarelevant arrhythmia53.9243.2639.3035.2643.3837.3844.01210 (175% of284 (135% of239 (191% of216 (94% of243 (115% of296 (133% of266 (114% ofpredicted)predicted)predicted)predicted)predicted)predicted)predicted)predicted)22.5427.5324.9020.3018.2324.9922.26	llow-up echocardiogram	59	53	59	52	53	59	52	58
Sinus rhythm, noSinus rhythm, noSinus rhythm, noSinus rhythm, noSinus rhythm, noSinus rhythm, norelevant arrhythmiarelevant arrhythmiarelevant arrhythmiarelevant arrhythmiarelevant arrhythmiarelevant arrhythmiaselevant arrhythmiarelevant arrhythmiarelevant arrhythmiarelevant arrhythmiarelevant arrhythmiarelevant arrhythmia53.9243.2639.3035.2643.3837.3844.01210 (175% of284 (135% of239 (191% of216 (94% of243 (115% of266 (114% ofpredicted)predicted)predicted)predicted)predicted)predicted)predicted)22.5427.5324.9020.3018.2324.9922.26	LVEF, %								
53.92 43.26 39.30 35.26 43.38 44.01 210 (175% of 284 (135% of 239 (191% of predicted) 216 (94% of 243 (115% of 296 (133% of 266 (114% of predicted)) 243 (115% of predicted) 266 (114% of predicted) 210 22.54 27.53 24.90 20.30 18.23 24.01	h ECG monitoring	Sinus rhythm, no relevant arrhythmia	Sinus rhythm, no relevant arrhythmia	Sinus rhythm, no relevant arrhythmia	Sinus rhythm, no relevant arrhythmia	Sinus rhythm, no relevant arrhythmia	Sinus rhythm, no relevant arrhythmia	Sinus rhythm, no relevant arrhythmia	Sinus rhythm, no relevant arrhythmia
Jkg/min 53.92 43.26 39.30 35.26 43.38 37.38 44.01 xercise 210 (175% of 284 (135% of 239 (191% of 216 (94% of 243 (115% of 296 (133% of 266 (114% of * predicted) predicted) predicted) predicted) predicted) lope 22.54 27.53 24.90 20.30 18.23 24.99 22.26	r uror espir ator y muress assessment								
210 (175% of 284 (135% of 239 (191% of 216 (94% of 243 (115% of 266 (114% of predicted) predicted) predicted) predicted) predicted) predicted) 22.54 27.53 24.90 20.30 18.23 24.99 22.26	VO _{2max} , mL/kg/min	53.92	43.26	39.30	35.26	43.38	37.38	44.01	77.91
predicted) predicted) predicted) predicted) predicted) predicted) predicted) ope 22:54 27.53 24.90 20.30 18.23 24.99 22.26	Maximum exercise	210 (175% of	284 (135% of	239 (191% of	216 (94% of	243 (115% of	296 (133% of	266 (114% of	321 (136% of
	capacity, W VE/VCO ₂ Slope	predicted) 22.54	predicted) 27.53	predicted) 24.90	predicted) 20.30	predicted) 18.23	predicted) 24.99	predicted) 22.26	predicted) 16.42

Table 1 Continued								
	Patient 1, marathon	Patient 2, marathon	Patient 3, half-marathon	Patient 4, half-marathon	Patient 5, marathon	Patient 6, marathon	Patient 7, half-marathon	Patient 8, half-marathon
medication	Daily lisdexamfetamine (30 mg/day) for ADHD	I		I	I	I		I
Doping								
follow-up blood pressure, mmHg	124/92	130/74	103/68	129/76	133/79	130/78	133/76	135/71
Running history	Experienced runner (14 years of training)	Yearly 10-kilometre races	Experienced runner	Novice	Former professional football player	Novice	Played professional football as a winger for 7 years until 2020	Participation in track and field since childhood with professional coaching
Training frequency		 4-6 training sessions 2-3 training sessions per week, eight per week (1x interval 20 km runs in training, 2x 8-10 km preparation runs) 	2–3 training sessions 3 training sessions a per week (1× interval week/weekly distance training, 2× 8–10 km 30 km runs)	6 training sessions per week, starting 6 months before	Approximately 60 km/week, with long-distance sessions and intervals	Resumed six years ago part of a consistent running routine, trains every other day	Trained 3-4 times weekly, focusing on strength and endurance	Interval runs and 3-4 track sessions weekly
Half/marathon experience	Experienced runner with 5 completed M	Finished one HM	10 finished HM since 2016					Finished one HM
Personal best	around 3 h M	1 h 40 min HM	1 h 52 min HM					1 h 20 min HM
Supplements, drugs, or doping								Occasionally used THC
Medical history	ADHS		Caught a cold 5 days before the race	I	I	Caught a cold two weeks before the race		Caught a cold 2 weeks before the race. with fever up to
								38.5°C
Occupation	Law student	Engineer	Medical student	Depositary	Finance consultant	Finance consultant	Business management student	Student of architecture
M marathon: HM half-marathon: S currence: P presencence hsTrenoninT high-cenetivity trenonin T. 1 VEF left ventricular ejection fraction	D. S. svacobe: P. presvacop	ve: hsTrononinT high-sensi	itivity troponin T: I VEE let	ft ventricular ejection fra	ction			

M, marathon; HM, half-marathon; S, syncope; P, presyncope; hsTroponinT, high-sensitivity troponin T; LVEF, left ventricular ejection fraction.

I felt extremely nauseous, unsure if I was going to vomit. When the ambulance arrived, my neurological symptoms gradually subsided. In the hospital, they gave me medication to relieve the nausea and pain. As I lay on the hospital bed, the symptoms disappeared entirely. Even my low BP did not bother me much.

When I was discharged, I felt weak and unsteady on my feet. Three days after the race, I developed a fever, but 2 days after that, I was back at work with no symptoms. A week later, I was able to start light training again. It was a scary experience, but I'm grateful for the help I received during the race.

Conclusion

This case series highlights the phenomenon of syncope and elevated biomarkers after intense and prolonged exercise and underscores the importance of proper marathon preparation and medical attention for participants. Even though findings suggested mainly orthostatic hypotension as mechanism for (pre-/)syncope, elevated cardiac biomarkers prompted sequential testing and additional tests to rule out acute coronary syndrome, SCAD, or peri-/myocarditis. Adequate training, medical examinations, and awareness of syncope causes are crucial for marathon participants. Caution and proper pacing are essential, particularly given the growing trend in marathon running.

Lead author biography



Dr Greta Hametner completed her training in internal medicine and cardiology at the University Hospital Zurich in Switzerland in 2023. She served as a Resident Physician in Cardiology and Intensive Care Medicine at Cantonal Hospital St. Gallen from 2017 to 2022. During an interim period, she held the position of Senior Physician in Internal Medicine at Cantonal Hospital Münsterlingen from 2020 to 2021. Dr Hametner's medical journey began with her role as a Resident Physician in Internal Medicine in 2015 in

Salzburg, Austria. She completed her medical education at the Medical University Graz, Austria, from 2009 to 2015. Her professional interests centre on sports cardiology, exercise testing, and advanced echocardiography, reflecting her dedication to enhancing cardiovascular care.

Consent: The authors confirm that written consent for submission and publication of the case series has been obtained from all patients in line with COPE guidance.

Conflict of interest: DN declares no conflict of interest related to this work; outside this work he received honoraria, consultant fees and/or travel expenses from Abbott, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Dr Willmar Schwabe GmbH & Co. KG, Emilwood Service Limited, Gerson Lehman Group (GLG) Consulting, Novartis, Novo Nordisk, Pfizer, walk and feel, and Zoll. All other authors have nothing to declare.

Funding: This case series was not supported by any funding.

Data availability

The data underlying this article will be shared upon reasonable request to the corresponding author.

References

- 1. Aengevaeren VL, Froeling M, Hooijmans MT, Monte JR, van den Berg-Faay S, Maria TE, et al. Myocardial injury and compromised cardiomyocyte integrity following a marathon run. *JACC Cardiovasc Imaging* 2020;**13**:1445–1447.
- Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, et al. 2018 ESC guidelines for the diagnosis and management of syncope. *Eur Heart J* 2018;39:1883–1948.
- Vitiello D, Palacin F, Poinsard L, Kirsch M, Jouini S, Billat V, et al. Marathon-induced cardiac fatigue: a review over the last decade for the preservation of the athletes' health. Int J Environ Res Public Health 2021;18:8676.
- Sanz-de la Garza M, Grazioli G, Bijnens BH, Sarvari SI, Guasch E, Pajuelo C, et al. Acute, exercise dose-dependent impairment in atrial performance during an endurance race: 2D ultrasound speckle-tracking strain analysis. *JACC Cardiovasc Imaging* 2016;9:1380–1388.
- Antonopoulos AS, Angelopoulos A, Tsioufis K, Antoniades C, Tousoulis D. Cardiovascular risk stratification by coronary computed tomography angiography imaging: current state-of-the-art. *Eur J Prev Cardiol* 2022;29:608–624.
- Gupta S, Meyersohn NM, Wood MJ, Steigner ML, Blankstein R, Ghoshhajra BB, et al. Role of coronary CT angiography in spontaneous coronary artery dissection. *Radiol Cardiothorac Imaging* 2020;2:e200364.
- Atkins WC, Butts CL, Kelly MR, Troyanos C, Laursen RM, Duckett A, et al. Acute kidney injury biomarkers and hydration outcomes at the Boston marathon. *Front Physiol* 2022;**12**: 813554.
- Aengevaeren VL, Baggish AL, Chung EH, George K, Kleiven Ø, Mingels AMA, et al. Exercise-induced cardiac troponin elevations: from underlying mechanisms to clinical relevance. *Circulation* 2021;**144**:1955–1972.
- Ristanović L, Cuk I, Villiger E, Stojiljković S, Nikolaidis PT, Weiss K, et al. The pacing differences in performance levels of marathon and half-marathon runners. *Front Psychol* 2023;14:1273451.
- Smyth B. How recreational marathon runners hit the wall: a large-scale data analysis of late-race pacing collapse in the marathon. *PLoS One* 2021;16:e0251513.